Corifollitropin alfa + RecFSH / Follitropin beta (Days 1 to 7) + Placebo Corifollitropin alfa + Placebo RecFSH / follitropin beta + RecFSH / Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
In Vitro Fertilization
Conditions
In Vitro Fertilization
Trial Timeline
Jun 27, 2006 → Jan 15, 2008
NCT ID
NCT00696800About Corifollitropin alfa + RecFSH / Follitropin beta (Days 1 to 7) + Placebo Corifollitropin alfa + Placebo RecFSH / follitropin beta + RecFSH / Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone
Corifollitropin alfa + RecFSH / Follitropin beta (Days 1 to 7) + Placebo Corifollitropin alfa + Placebo RecFSH / follitropin beta + RecFSH / Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone is a phase 3 stage product being developed by Organon for In Vitro Fertilization. The current trial status is completed. This product is registered under clinical trial identifier NCT00696800. Target conditions include In Vitro Fertilization.
What happened to similar drugs?
1 of 3 similar drugs in In Vitro Fertilization were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00696800 | Phase 3 | Completed |
Competing Products
8 competing products in In Vitro Fertilization